Fri, Dec 19, 2014, 12:43 PM EST - U.S. Markets close in 3 hrs 17 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • jsblvbjb jsblvbjb Jul 7, 2013 12:14 PM Flag

    Jad's post on Motley Fool summed it up!

    Great response Jad! Here it is for everyone else:
    "You seem to have left out that six analysts either maintained or upgraded Insmed after the results, that the sp has moved back up three days in a row, that Arikace was deemed to be comparable to TOBI, that Arikace is a once a day dosing vs twice per day for TOBI and that TOBI users fail to dose twice per day at a rate of 30% to 40%. In their comparison trial TOBI users were forced to dose twice per day. The trial was not reflective of actual use but optimum use - and they were head to head anyway. In addition the beneficial effects of Arikace grew stronger over time while the beneficial effect of TOBI dropped to zero. The Company also announces that the U.S. Food and Drug Administration (FDA) designated ARIKACE as a Qualified Infectious Disease Product (QIDP) for the treatment of Non-Tuberculous Mycobacteria (NTM) lung infections. Additionally, the FDA granted Fast Track designation to ARIKACE for the treatment of NTM. There is no other treatment for NTM in existence today. You might want to consider publishing the entire story rather than this half #$%$ analysis. We'll see you at $25 per share by yearend or sooner. Then you can eat crow publicly."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The Motley Fool statement that the analyst do not see upside potential even if FDA approved is plain wrong.

    • It's really interesting. I watched 11 thumbs down come up in a period of about 12 minutes. I think that someone actually has at least 10 ids that they use to diss people. It's either a pretty warped human being or someone who's paid to be a warped human being. Either way, the party is now over for these folks and we are about to finally, after almost a decade, get to the end of the rainbow.

      Sentiment: Buy

 
INSM
16.31+0.26(+1.62%)12:42 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.